iSpecimen Raises $400,000 in Series D Preferred Stock Offering

iSpecimen raised $400,000 through a private placement of 500 Series D convertible preferred shares, with proceeds for working capital. The shares have an $8% annual dividend and conversion terms. The offering includes resale registration rights, E.F. Hutton's placement services, and a 90-day lock-up for insiders. According to the company, the financing is intended for general corporate purposes.

Original reporting
Published Nov 9, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
iSpecimen Raises $400,000 in Series D Preferred Stock Offering — source image
Decision brief

The 30-second read

$ISPCNeutralLow
01

Why it matters

The $400k raise is a primary disclosure but small in scale, likely causing modest dilution and limited market reaction.

02

Market read

Primary micro‑cap capital raise with limited immediate price impact.

03

What to watch

Potential strategic partnership with E.F. Hutton and the convertible terms may become material if the company secures larger financing later.

Relevance 5/10Novelty 5/10Timing: same-day announcement

Background

iSpecimen (ISPC) is a micro‑cap biotech that filed an 8‑K reporting a private placement of Series D convertible preferred shares.

Company-level read

Ticker impact

$ISPCNeutralHigh confidence
Context

iSpecimen disclosed a $400,000 Series D convertible preferred stock private placement to fund working capital.

Expected impact

likely slight downward pressure as market prices in the new preferred shares

Evidence & confidence

The raise is modest in size for a micro‑cap, but introduces convertible preferred shares that could dilute existing equity if converted.

Market effects

Minimal impact on the broader biotech/health‑tech sector.

Limited to U.S. micro‑cap investors.

Low

Counterpoint

The raise could be seen as a sign of confidence and may support a short‑term rally if the capital is deployed effectively.

Key entities

  • iSpecimen Inc.

    Issuer of the Series D preferred stock.

  • E.F. Hutton

    Placement agent for the private offering.

Related articles

$BALYMedAI 8/10

BALLY’S CORPORATION SECURES $560 MILLION OF ADDITIONAL FINANCING Proceeds to be Used to Repay Outstanding Debt, for General Corporate Purposes and to Fund…

Bally's Corp (BALY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 BALLY’S CORPORATION SECURES $560 MILLION OF ADDITIONAL FINANCING Proceeds to be Used to Repay Outstanding Debt, for General Corporate Purposes and to Fund Additional Development of Bally’s Chicago PROVIDENCE, R.I., November 17, 2026 — Bally’s Corporation (NYSE: BALY)